Table. 1.

Table. 1.

Published Reports on TPO-RAs in WAS patients

References Number of patients Platelet count TPO-RAs Platelet response Bleeding phenotype
[6] 1 10-20,000/mL Eltrombopag 30,000 Significantly
reduced bleeding
[12] 1 <20,000/mL Eltrombopag after HSCT No response Not commented
[4] 8 <50,000/mL Eltrombopag
5/8 doubled baseline count or increased >50,000/mL
(1/3 non responders switched to romiplostim – increased >20,000/mL)
Reduced bleeding
[5] 67 <61,000/mL Romiplostim 40 out of 67 >30,000/mL Reduced bleeding even in non-responders

TPO-RAs, thrombopoietic receptor agonists; HSCT, hematopoietic stem cell transplantation.

Clin Pediatr Hematol Oncol 2022;29:12-6
© 2022 Clin Pediatr Hematol Oncol